种系DDX41突变髓系恶性肿瘤患者中的异基因造血干细胞移植
该研究报道了83例种系DDX41突变MDS/AML患者的造血干细胞移植结局,中位随访4.4年,2年无白血病生存率为68.6%,2年非复发死亡率为21.1%;配对分析显示DDX41突变与野生型患者在2年无白血病生存率等方面无显著差异,但DDX41突变患者复发呈现1年内较低、1年后较高的趋势,并发现7例DDX41突变供者细胞白血病。
要点
- 83例DDX41突变MDS/AML患者移植后2年无白血病生存率68.6%,2年非复发死亡率21.1%。
- 配对分析显示DDX41突变与野生型患者2年无白血病生存率无显著差异(HR 1.06)。
- DDX41突变患者复发呈1年内较低、1年后较高的趋势,发现7例供者细胞白血病。
核心结论
- 种系DDX41突变MDS/AML患者接受造血干细胞移植未增加毒性风险,但观察到潜在晚期复发可能,或可通过根据DDX41状态选择相关供者来减轻。
研究设计与样本
- 研究报告了83例种系DDX41突变MDS/AML患者的造血干细胞移植结局,并利用AML临床试验中接受移植的患者进行配对匹配分析评估DDX41突变的影响。
主要发现
- 中位随访4.4年,2年无白血病生存率为68.6%(95%CI 57.1-77.6),2年非复发死亡率为21.1%(95%CI 12.9-30.6)。
- 配对分析中,DDX41突变与DDX41野生型患者2年无白血病生存率无显著差异(HR 1.06;95%CI 0.59-1.90;P=.84),总生存、非复发死亡、复发及移植物抗宿主病发生率亦无显著差异。
- DDX41突变患者复发累积发生率显示1年内复发率较低、1年后较高的趋势。
- 在接受相关供者移植后复发的患者中,鉴定出7例DDX41突变供者细胞白血病。
临床怎么用
- 作者认为,根据DDX41状态选择相关供者可能减轻移植后晚期复发风险。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Germ line DDX41 mutations (DDX41mut) are identified in ∼5% of myeloid malignancies with an excess of blasts, representing a distinct myelodysplastic syndrome (MDS)/acute myeloid leukemia (AML) entity. The disease is associated with better outcomes than DDX41 wild-type (DDX41WT) cases, but patients who do not undergo allogeneic hematopoietic stem cell transplantation (HSCT) may experience late relapse. Because of the recent identification of DDX41mut, data on the post-HSCT outcomes remain limited. In this study, we report the HSCT outcomes of 83 patients with DDX41mut MDS/AML. With a median follow-up of 4.4 years, the 2-year leukemia-free survival (LFS) was 68.6% (95% confidence interval [CI], 57.1-77.6) and the 2-year nonrelapse mortality (NRM) was 21.1% (95% CI, 12.9-30.6). We then assessed the impact of DDX41mut using a pair match analysis performed on patients who underwent a transplantation in AML clinical trials. No significant differences were observed between patients with DDX41mut and those with DDX41WT in terms of LFS at 2 years (hazard ratio, 1.06; 95% CI, 0.59-1.90; P = .84), overall survival, NRM, relapse, or graft-versus-host disease incidence. The cumulative incidence of relapse for DDX41mut showed a trend toward a lower relapse rate during the first year then higher after 1 year. Given the familial nature of the disease, we specifically examined patients who relapsed after HSCT with a related donor and identified 7 cases of DDX41mut donor cell leukemia. In this study, HSCT in patients with DDX41mut AML was not associated with an increased risk for toxicity. However, we observed a potential for later relapse, which could potentially be mitigated by selecting related donors based on DDX41 status.
引用
- Loschi M, Villy MC, Galimard JE, et al. Allogeneic hematopoietic stem cell transplantation in patients with germ line DDX41 mutated myeloid malignancies. Blood Adv. 2025. PMID: 40924929. doi:10.1182/bloodadvances.2025017084
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。